Hindustan Bio Sciences Limited (BOM:532041)
India
· Delayed Price · Currency is INR 9.21
0.00 (0.00%)
At close: Apr 28, 2026
Hindustan Bio Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 10.96 | 8.13 | 10.53 | 9.22 | 4.31 | 10.32 | Upgrade
|
| Other Revenue | 0.4 | - | - | - | - | - | Upgrade
|
| Revenue | 11.35 | 8.13 | 10.53 | 9.22 | 4.31 | 10.32 | Upgrade
|
| Revenue Growth (YoY) | 40.06% | -22.75% | 14.15% | 114.19% | -58.27% | -46.90% | Upgrade
|
| Cost of Revenue | 6.89 | 4.97 | 6.44 | 5.79 | 2.48 | 6.92 | Upgrade
|
| Gross Profit | 4.46 | 3.16 | 4.09 | 3.44 | 1.82 | 3.4 | Upgrade
|
| Selling, General & Admin | 1.79 | 1.32 | 1.65 | 2.62 | 2.53 | 2.58 | Upgrade
|
| Other Operating Expenses | 1.06 | 0.84 | 1.8 | 1.1 | 4.31 | 10.14 | Upgrade
|
| Operating Expenses | 2.99 | 2.17 | 3.52 | 3.77 | 6.87 | 12.8 | Upgrade
|
| Operating Income | 1.47 | 1 | 0.57 | -0.34 | -5.05 | -9.4 | Upgrade
|
| Interest Expense | -0 | - | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | -0.05 | -0.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.02 | -0.02 | -0.04 | -0.04 | -0.05 | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | 1.45 | 0.98 | 0.53 | -0.38 | -5.14 | -9.55 | Upgrade
|
| Pretax Income | 1.45 | 0.98 | 0.53 | -0.38 | -5.14 | -9.55 | Upgrade
|
| Income Tax Expense | -0.03 | -0.03 | -0.04 | 0.03 | 0.03 | -0.15 | Upgrade
|
| Net Income | 1.48 | 1.01 | 0.58 | -0.4 | -5.18 | -9.4 | Upgrade
|
| Net Income to Common | 1.48 | 1.01 | 0.58 | -0.4 | -5.18 | -9.4 | Upgrade
|
| Net Income Growth | 326.30% | 74.83% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 | Upgrade
|
| Shares Change (YoY) | -10.45% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.16 | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.10 | 0.06 | -0.04 | -0.50 | -0.92 | Upgrade
|
| EPS Growth | 376.06% | 74.83% | - | - | - | - | Upgrade
|
| Free Cash Flow | - | 0.27 | -14.09 | -0.5 | -3.46 | 7.53 | Upgrade
|
| Free Cash Flow Per Share | - | 0.03 | -1.38 | -0.05 | -0.34 | 0.73 | Upgrade
|
| Gross Margin | 39.31% | 38.89% | 38.84% | 37.26% | 42.33% | 32.94% | Upgrade
|
| Operating Margin | 12.95% | 12.25% | 5.42% | -3.67% | -117.17% | -91.08% | Upgrade
|
| Profit Margin | 13.03% | 12.38% | 5.47% | -4.39% | -120.19% | -91.08% | Upgrade
|
| Free Cash Flow Margin | - | 3.33% | -133.83% | -5.40% | -80.41% | 72.97% | Upgrade
|
| EBITDA | 1.42 | 1 | 0.64 | -0.28 | -5.01 | -9.32 | Upgrade
|
| EBITDA Margin | 12.53% | 12.27% | 6.07% | -3.06% | -116.38% | -90.30% | Upgrade
|
| D&A For EBITDA | -0.05 | 0 | 0.07 | 0.06 | 0.03 | 0.08 | Upgrade
|
| EBIT | 1.47 | 1 | 0.57 | -0.34 | -5.05 | -9.4 | Upgrade
|
| EBIT Margin | 12.95% | 12.25% | 5.42% | -3.67% | -117.17% | -91.08% | Upgrade
|
| Revenue as Reported | 11.35 | 8.13 | 10.53 | 9.22 | 4.31 | 10.32 | Upgrade
|
| Advertising Expenses | - | 0.05 | 0.07 | 0.07 | 0.06 | 0.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.